American Association for Cancer Research
Browse
00085472can142946-sup-138931_2_supp_2929908_nmgt7t.docx (17.77 kB)

Supplementary Tables S1-S3 from G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation

Download (17.77 kB)
journal contribution
posted on 2023-03-30, 23:09 authored by Saurabh Agarwal, Anna Lakoma, Zaowen Chen, John Hicks, Leonid S. Metelitsa, Eugene S. Kim, Jason M. Shohet

Supplementary Tables S1-S3. IC50 for different drug combinations (S1); Gene Ontology analysis for genes upregulated in CD114+ cells (S2); Primers used in the study (S3).

History

ARTICLE ABSTRACT

Increasing evidence suggests that inflammatory cytokines play a critical role in tumor initiation and progression. A cancer stem cell (CSC)-like subpopulation in neuroblastoma is known to be marked by expression of the G-CSF receptor (G-CSFR). Here, we report on the mechanistic contributions of the G-CSFR in neuroblastoma CSCs. Specifically, we demonstrate that the receptor ligand G-CSF selectively activates STAT3 within neuroblastoma CSC subpopulations, promoting their expansion in vitro and in vivo. Exogenous G-CSF enhances tumor growth and metastasis in human xenograft and murine neuroblastoma tumor models. In response to G-CSF, STAT3 acts in a feed-forward loop to transcriptionally activate the G-CSFR and sustain neuroblastoma CSCs. Blockade of this G-CSF–STAT3 signaling loop with either anti-G-CSF antibody or STAT3 inhibitor depleted the CSC subpopulation within tumors, driving correlated tumor growth inhibition, decreased metastasis, and increased chemosensitivity. Taken together, our results define G-CSF as a CSC-activating factor in neuroblastoma, suggest a comprehensive reevaluation of the clinical use of G-CSF in these patients to support white blood cell counts, and suggest that direct targeting of the G-CSF–STAT3 signaling represents a novel therapeutic approach for neuroblastoma. Cancer Res; 75(12); 2566–79. ©2015 AACR.